CGON stock forecast, quote, news & analysis
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer... Show more
Why CG Oncology (CGON) Stock Is Down -17% in the Last 30 Days
Key Takeaways
- CG Oncology shares have pulled back roughly 17% over the last 30 days, retreating from near $74–$75 to the low-$60s.
- The decline reflects profit-taking after a strong multi-month rally rather than a single negative company-specific event.
- Over the trailing quarter, the stock is down about 12%, having peaked near its 52-week high of $80.97 in August before correcting.
- The core investment narrative is unchanged: a rolling Biologics License Application (BLA) for cretostimogene grenadenorepvec is expected to be completed in the fourth quarter of 2026.
- A robust balance sheet — with more than $1 billion in cash and equivalents — is expected to fund operations through 2029.
CG Oncology (CGON) Company Overview and Market Position
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company headquartered in Dallas, Texas, focused on developing and commercializing a potential bladder-sparing therapy for patients with bladder cancer. Its lead candidate, cretostimogene grenadenorepvec, is an investigational oncolytic immunotherapy delivered directly into the bladder (intravesically) for the treatment of non-muscle invasive bladder cancer (NMIBC).
The company is advancing the candidate across a broad late-stage program, including the Phase 3 BOND-003 study in high-risk, BCG-unresponsive NMIBC and the Phase 3 PIVOT-006 study in intermediate-risk NMIBC. Investors follow CGON closely because cretostimogene is positioned as a potential backbone therapy in a market with no currently approved FDA therapies for certain NMIBC populations, offering a differentiated bladder-sparing alternative with a favorable safety profile.
CG Oncology (CGON) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CGON shares have declined approximately 17%, falling from a closing level near $74.62 to around $61.93 as of the most recent trading session. The decline accelerated in late September and early October, when the stock dropped from the mid-$70s through the $60s.
The quarterly picture tells a similar, though slightly more moderate, story. About three months ago the stock traded near $70, then rallied to a 52-week intraday high of $80.97 in mid-August before reversing lower. Measured over the trailing quarter, CGON is down roughly 12%, meaning the recent 30-day decline accounts for the bulk of the quarter's weakness following that August peak.
What Drove CGON Stock Price in the Last 30 Days
The recent pullback does not appear tied to any single negative clinical or regulatory announcement. Instead, the move looks consistent with profit-taking and a broader rotation out of speculative, high-beta biotechnology names after a lengthy run-up. Shares had gained more than 60% over a six-month stretch and roughly doubled on a year-over-year basis, leaving the stock vulnerable to consolidation once upward momentum stalled near its all-time high.
During this window, company news flow centered on commercial-readiness rather than new efficacy data. In October, the company appointed Isabel Kalofonos as Chief Commercial Officer to lead launch planning ahead of a potential approval — a step that signals preparation for commercialization but does not itself represent a new clinical catalyst. Broader weakness across the small-cap biotech complex and a lack of near-term data readouts likely compounded the selling pressure as the stock broke below key technical levels, including its 50-day and 200-day moving averages.
What Drove CGON Stock Performance Over the Last Quarter
The quarter's broader narrative is one of a strong rally followed by a sharp correction. Early in the period, shares climbed on optimism around cretostimogene's clinical momentum — including durable Phase 3 BOND-003 data and an accelerated timeline for the PIVOT-006 trial — before peaking near $81. From there, investors appeared to take gains and reassess risk as the company's next major catalyst, the BLA submission, remained months away.
Longer term, the investment thesis has not fundamentally changed: cretostimogene continues to advance toward a first BLA, with positive data published in The Lancet Oncology supporting the lead program, and management expects to complete the BLA submission for high-risk, BCG-unresponsive NMIBC in the fourth quarter of 2026. The quarterly decline therefore appears to reflect valuation and sentiment dynamics more than any deterioration in the company's underlying fundamentals.
Trending AI Robots
For investors seeking a more systematic approach to navigating volatility in names like CGON, Tickeron's Trending AI Robots page offers a curated view of the platform's active trading strategies. Tickeron provides hundreds of AI-driven trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. Each bot varies in strategy, timeframe, and performance metrics, allowing users to explore approaches ranging from short-term technical signals to longer-horizon momentum models. Exploring this curated selection can help traders identify data-driven strategies aligned with their own risk tolerance and time horizon.
CGON Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most significant catalyst for CGON is the expected completion of its BLA submission for cretostimogene in high-risk, BCG-unresponsive NMIBC during the fourth quarter of 2026. Regulatory feedback, including any alignment discussions with the FDA, will be closely watched. Investors should also monitor the timing of top-line data from the Phase 3 PIVOT-006 study and durability readouts from the BOND-003 and CORE-008 programs.
Other factors include the company's progress in building its commercial organization, competitive developments from peers such as JNJ and IBRX, and broader macro conditions affecting high-beta biotech valuations. Quarterly earnings and cash-burn trends remain important, though the company's strong cash position reduces near-term financing risk.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CGON's RSI Indicator recovers from oversold territory
The RSI Indicator for CGON moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 12 similar instances when the indicator left oversold territory. In 11 of the 12 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 23 of 26 cases where CGON's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
Following a +3.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGON advanced for three days, in 118 of 146 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CGON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 24, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CGON as a result. In 39 of 48 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for CGON turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 27 similar instances when the indicator turned negative. In 22 of the 27 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
CGON moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CGON crossed bearishly below the 50-day moving average on September 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for CGON entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.361) is normal, around the industry mean (2.988). P/E Ratio (-23.138) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. CGON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology